Want to see IT:ELN full AI Analyst Report?
Top Page
El.En. S.p.A.
(ELN)
Select Model
Select Model
Rating:67Neutral
Price Target:
€17.50
▲(13.27% Upside)
Action:Reiterated
Date:09/12/26
The score is primarily supported by a strong, conservatively financed balance sheet and improved recent free cash flow. It is held back by 2025 margin compression and currently weak technical momentum signals (negative MACD and low RSI). Valuation is broadly reasonable, providing moderate support but not enough to offset the near-term profitability and momentum concerns.
Positive Factors
Conservative Balance Sheet
Debt-to-equity of about 0.09, alongside improving debt levels and steadily growing equity, indicates conservative financing. This provides resilience through demand cycles and preserves flexibility to invest in product development, service capacity, or market expansion without relying heavily on borrowing.
Negative Factors
2025 Margin Compression
Gross-margin compression and a lower net margin in 2025 show that recent revenue growth has not translated proportionally into profitability. If this pressure persists, it could reduce operating leverage, constrain reinvestment, and weaken the earnings contribution of future sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Debt-to-equity of about 0.09, alongside improving debt levels and steadily growing equity, indicates conservative financing. This provides resilience through demand cycles and preserves flexibility to invest in product development, service capacity, or market expansion without relying heavily on borrowing.
Read all positive factors
El.En. S.p.A. (ELN) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€1.32B
Dividend Yield1.57%
Average Volume (3M)40.17K
Price to Earnings (P/E)13.9
Beta (1Y)1.00
Revenue Growth2.55%
EPS Growth22.08%
CountryIT
Employees1,412
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.89
Shares Outstanding80,451,256
10 Day Avg. Volume78,419
30 Day Avg. Volume40,167
Financial Highlights & Ratios
PEG Ratio-1.65
Price to Book (P/B)2.71
Price to Sales (P/S)1.89
P/FCF Ratio18.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.10Price Target Upside23.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.75
Revenue Forecast (FY)€504.64M
El.En. S.p.A. Business Overview & Revenue Model
Company Description
EL.En. S.p.A. is a global leader in the development, manufacturing, marketing, and distribution of advanced laser systems. The company supplies a wide array of medical laser equipment for applications in physiotherapy, orthopedics, traumatology, r...
How the Company Makes Money
El.En. makes money mainly by selling laser-based equipment and systems and by providing related services and consumables tied to its installed base. Key revenue streams include: (1) Sales of medical and aesthetic laser devices: revenue generated f...
El.En. S.p.A. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
84
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 551.97M | 590.85M | 565.85M | 692.29M | 673.58M | 571.40M |
| Gross Profit | 186.45M | 253.70M | 238.80M | 252.08M | 243.47M | 206.09M |
| EBITDA | 112.62M | 84.82M | 97.35M | 83.94M | 90.71M | 76.59M |
| Net Income | 51.58M | 43.41M | 51.61M | 48.24M | 55.11M | 45.44M |
Balance Sheet | ||||||
| Total Assets | 633.37M | 627.88M | 740.72M | 719.21M | 735.89M | 650.69M |
| Cash, Cash Equivalents and Short-Term Investments | 195.54M | 211.44M | 157.49M | 135.36M | 165.13M | 182.45M |
| Total Debt | 10.86M | 38.07M | 46.72M | 73.63M | 82.92M | 60.50M |
| Total Liabilities | 197.77M | 200.41M | 329.92M | 343.75M | 379.25M | 362.99M |
| Stockholders Equity | 420.17M | 411.72M | 385.02M | 346.03M | 313.19M | 269.37M |
Cash Flow | ||||||
| Free Cash Flow | 57.05M | 60.08M | 73.61M | -1.14M | -16.31M | 63.35M |
| Operating Cash Flow | 63.20M | 70.81M | 83.07M | 12.22M | 2.12M | 79.48M |
| Investing Cash Flow | 1.73M | -12.97M | 68.68K | -16.97M | -30.15M | -20.23M |
| Financing Cash Flow | -8.69M | -30.70M | -47.99M | -24.79M | 10.25M | -3.51M |
El.En. S.p.A. Technical Analysis
Neutral
15.45
Price Trends
15.62
Positive
15.78
Negative
14.51
Positive
Market Momentum
0.15
Negative
49.29
Neutral
42.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:ELN, the sentiment is Neutral. The current price of 15.45 is below the 20-day moving average (MA) of 15.65, below the 50-day MA of 15.62, and above the 200-day MA of 14.51, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 42.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IT:ELN.
El.En. S.p.A. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | €10.90B | 21.77 | 24.74% | 2.53% | 9.10% | 22.99% | |
73 Outperform | €4.11B | 24.33 | 13.91% | 1.66% | -3.13% | -22.16% | |
67 Neutral | €1.32B | 13.85 | 17.54% | 1.57% | 2.55% | 22.08% | |
58 Neutral | €407.86M | 25.75 | ― | 4.16% | 6.80% | -84.47% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IT:ELN
El.En. S.p.A.
15.71
4.96
46.17%
IT:DIA
DiaSorin S.p.A.
78.54
5.73
7.87%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
53.00
3.62
7.33%
IT:GHC
Garofalo Health Care S.P.A.
5.38
0.53
10.97%
IT:GPI
GPI SpA
14.22
-3.43
-19.42%
IT:IMD
I.M.D. International Medical Devices S.P.A.
1.32
-0.06
-4.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.